CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: February 1, 2011
Result type: Reports
Project Number: SR0224-000
Product Line: Reimbursement Review

Generic Name: Tapentadol

Brand Name: Nucynta CR

Manufacturer: Janssen Inc.

Therapeutic Area: Pain, moderate to moderately severe

Indications: Pain, moderate to moderately severe

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: September 28, 2011

Recommendation Type: Do not list